Antimicrobial Guidelines - EPUT
[pic]
Management of infection guidance for North Essex Partnership NHS Foundation Trust
Produced July 2016
Review due July 2019
Summary tables: infections in primary care
|Principles of Treatment |
| |
|This guidance is based on the best available evidence but use professional judgement and involve patients in management decisions. |
|It is important to initiate antibiotics as soon as possible in severe infection. |
|Where an empirical therapy has failed or special circumstances exist, microbiological advice can be obtained from the consultant microbiologist team on 01206 |
|747374. Dr Gillian Urwin (Consultant Microbiologist) is the lead microbiologist for NEPFT. Out- of-hours please consult the on-call microbiologist via 01206 747474.|
|Prescribe an antibiotic only when there is likely to be a clear clinical benefit. Please state the indication clearly and the intented course length or review date.|
|Consider a ‘No’ or ‘Back-up/Delayed’, antibiotic strategy for acute self-limiting upper respiratory tract infections,1A+ and mild UTI symptoms. |
|Limit prescribing over the telephone to exceptional cases. |
|Use simple generic antibiotics if possible. Avoid broad spectrum antibiotics (eg. co-amoxiclav, quinolones and cephalosporins) when narrow spectrum antibiotics |
|remain effective, as they increase risk of Clostridium difficile, MRSA and resistant UTIs. |
|A dose and duration of treatment for adults is usually suggested, but may need modification for age, weight and renal function. In severe or |
|recurrent cases consider a larger dose or longer course. |
|Child doses are provided when appropriate or can be accessed via the childrens BNF. |
|Please refer to BNF for further dosing and interaction information (e.g. interaction between macrolides and statins) if needed and please check for |
|hypersensitivity. |
|Lower threshold for antibiotics in immunocompromised or those with multiple morbidities; consider culture and seek advice. |
|Avoid widespread use of topical antibiotics (especially those agents also available as systemic preparations, e.g. fusidic acid). |
|In pregnancy take specimens to inform treatment; where possible avoid tetracyclines, aminoglycosides, quinolones, high dose metronidazole (2 g) unless benefit |
|outweighs risks. Short-term use of nitrofurantoin (at term, theoretical risk of neonatal haemolysis) is not expected to cause foetal problems. Trimethoprim is also |
|unlikely to cause problems unless poor dietary folate intake or taking another folate antagonist eg antiepileptic. |
|This guidance should not be used in isolation; it should be supported with patient information about back-up/delayed antibiotics, infection severity and usual |
|duration, clinical staff education, and audits. Materials are available on the RCGP TARGET website. |
|This guideline is based on the Public Health England full guideline which can be accessed through |
|.uk/government/publications/managing-common-infections-guidance-for-primary-care |
|ILLNESS |
|Influenza treatment |Annual vaccination is essential for all those at risk of influenza. For otherwise healthy adults antivirals not recommended. |
|PHE Influenza |Treat ‘at risk’ patients, when influenza is circulating in the community and ideally within 48 hours of onset (do not wait for lab report) or |
| |in a care home where influenza is likely. At risk: pregnant (including up to two weeks post-partum), 65 years or over, chronic respiratory |
|For prophylaxis see:|disease (including COPD and asthma), significant cardiovascular disease (not hypertension), immunocompromised, diabetes mellitus, chronic |
|NICE Influenza |neurological, renal or liver disease, morbid obesity (BMI>=40). Use 5 days treatment with oseltamivir 75mg bd. If resistance to oseltamivir or |
| |severe immunosuppression, use zanamivir 10mg BD (2 inhalations by diskhaler for up to 10 days) and seek advice. See PHE Influenza guidance for |
| |treatment of patients under 13 years or in severe immunosuppression (and seek advice). |
|Acute sore throat |Avoid antibiotics as 90% resolve in 7 days1A+ without,|Phenoxymethylpenicillin5B- |500mg QDS |10 days 8A- |
|CKS |and pain only reduced by 16 hours.2A+ Use FeverPAIN | |or 1G BD6A+(QDS when severe7D) | |
| |Score: Fever in last 24h, Purulence, Attend rapidly | | | |
|FeverPAIN |under 3d, severely Inflamed tonsils, No cough or |Penicillin Allergy: | | |
| |coryza).3B+,4B+ Score 0-1: 13-18% streptococci, use |clarithromycin |250-500mg BD | |
| |NO antibiotic strategy; 2-3: 34-40% streptococci, use | | |5 days 9A+ |
| |3 day back-up antibiotic; >4: 62-65% streptococci, use| | | |
| |immediate antibiotic if severe, or 48hr short back-up| | | |
| |prescription.5A- | | | |
| |Always share self-care advice & safety net. | | | |
| |Antibiotics to prevent Quinsy NNT >4000.4B- | | | |
| |Antibiotics to prevent Otitis media NNT 200.2A+ | | | |
| |10d penicillin lower relapse vs 7d in 65yrs with 2 of above. | | | |
| |Consider CRP test1A,4 if antibiotic being considered. | | | |
| |If CRP100mg immediate antibiotics. | | | |
|Acute exacerbation|Treat exacerbations promptly with antibiotics if |Amoxicillin |500mg TDS |5 days4C |
|of COPD |purulent sputum and increased shortness of breath and/or|or doxycycline |200mg stat/100mg OD |5 days4C |
|NICE 12 |increased sputum volume.1-3B+ |or clarithromycin |500mg BD |5 days4A |
| |Risk factors for antibiotic resistant organisms include | | | |
|GOLD |co-morbid disease, severe COPD, frequent exacerbations, |If resistance: co-amoxiclav |625mg TDS |5 days4A |
| |antibiotics in last 3 months.2 | | | |
|Community acquired|Use CRB65 score to guide mortality risk, place of care &|IF CRB65=0: amoxicillinA+ | | CRB65=0: use |
|pneumonia- |antibiotics1 Each CRB65 parameter scores 1: Confusion |or clarithromycin A- |500mg TDS |5 days. Review |
|treatment in the |(AMT30/min; |or doxycyclineD |500mg BD |at 3 days & |
|community2,3 |BP systolic 65; |If CRB65=1,2 & AT HOME, |200mg stat/100mg OD |extend to 7-10 days if|
|BTS 2009 |Score 3-4 urgent hospital admission; Score 1-2 |clinically assess need for dual | |poor |
| |intermediate risk consider hospital assessment; Score 0 |therapy for atypicals: | |response. |
|NICE 191 |low risk: consider home based care. |amoxicillin A+ | | |
| |Always give safety-net advice and likely duration of |AND clarithromycin A- | |7-10 days |
| |symptoms. Mycoplasma infection is rare in >65s.1 |or doxycycline alone |500mg TDS | |
| | | |500mg BD | |
| | | |200mg stat/100mg OD | |
|URINARY TRACT INFECTIONS – refer to PHE UTI guidance for diagnosis information |
|As E. coli bacteraemia in the community is increasing ALWAYS safety net and consider risks for resistance 1C |
|UTI in adults |Treat women with severe/or ≥ 3 symptoms;1, 2A, 3C |Nitrofurantoin8B+ 9C 10B+ |100mg m/r BD11C | |
|(no fever or flank|women mild/or ≤ 2 symptoms AND Urine | |200mg BD |Women all ages 3 |
|pain) |NOT cloudy 97% negative predictive value, do not treat |Trimethoprim 7B+ |200mg TDS13,29,30A |days2,12,13A+ |
|PHE URINE |unless other risk factors for infection. If cloudy |Pivmecillinam13,21,22,29,30A |400mgTDS13 |Men 7 days1,5C |
| |urine use dipstick to guide treatment. Nitrite plus |(400mg if resistance risk) | | |
|SIGN |blood or leucocytes has 92% positive predictive value; |If organism susceptible: | | |
| |nitrite, leucocytes, blood all negative 76% NPV.4A- |amoxicillin14B+ | | |
|CKS women, |Consider a back-up / delayed antibiotic option.20A | |500mg TDS | |
| | | | | |
|CKS men |Men: Consider prostatitis and send pre-treatment MSU1,5C| | | |
| |OR if symptoms mild/non-specific, use negative dipstick | | | |
|RCGP UTI clinical |to exclude UTI.6C | | | |
|module |Always safety net. | | | |
| |First line: nitrofurantoin if GFR over 45ml/min.24-5 | | | |
|SAPG UTI |GFR 30-45: only use if resistance & no alternative. In | | | |
| |treatment failure: always perform culture.1B | | | |
| | |Use nitrofurantoin first line as general resistance and community multi-resistant. |
| | |Extended-spectrum Beta-lactamase E. coli are increasing. Trimethoprim (if low risk of |
| | |resistance) and pivmecillinam are alternative first line agents. |
| | |Risk factors for increased resistance include: care home resident, recurrent UTI, |
| | |hospitalisation >7d in the last 6 months, unresolving urinary symptoms, recent travel to|
| | |a country with increased antimicrobial resistance (outside Northern Europe and |
| | |Australasia) especially health related, previous known UTI resistant to trimethoprim, |
| | |cephalosporins or quinolones.19 |
| | |If increased resistance risk, send culture for susceptibility testing & give safety net |
| | |advice. If GFR 65 years: do not treat asymptomatic bacteriuria; it is common but is not associated with increased morbidity.1B+ |
|Catheter in situ: antibiotics will not eradicate asymptomatic bacteriuria; only treat if systemically unwell or pyelonephritis likely.2B+ |
|Do not use prophylactic antibiotics for catheter changes unless history of catheter-change-associated UTI or trauma (NICE, SIGN).3B |
|Acute prostatitis |Send MSU for culture and start antibiotics.1C |Ciprofloxacin1C |500mg BD |28 days1C |
|BASHH, CKS |4-wk course may prevent chronic prostatitis.1C |or ofloxacin1C |200mg BD |28 days1C |
| |Quinolones achieve higher prostate levels.2 |2nd line: trimethoprim1C |200mg BD |28 days1C |
|UTI in pregnancy |Send MSU for culture and start antibiotics.1A |First line: nitrofurantoin |100mg m/r BD | |
|PHE URINE |Short-term use of nitrofurantoin in pregnancy is |IF susceptible, amoxicillin | | |
|CKS |unlikely to cause problems to the foetus.2C |Second line: trimethoprim |500mg TDS |All for 7 days6C |
|UKtis |Avoid trimethoprim if low folate status3 or on folate |Give folate if 1st trimester | | |
| |antagonist (eg antiepileptic or proguanil).2 |Third line: cefalexin4C, 5B- |200mg BD (off-label) | |
| | | | | |
| | | |500mg BD | |
|UTI in Children |Child ................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related searches
- manuscript guidelines for publication
- submission guidelines for a novel
- manuscript guidelines for authors
- hypertrophic cardiomyopathy guidelines u
- hypertrophic cardiomyopathy guidelines acc
- hypertrophic cardiomyopathy guidelines update
- hypertrophic cardiomyopathy guidelines 2017
- clinical guidelines for conjunctivitis
- guidelines for management of stemi
- federal guidelines for salaried employees
- antimicrobial eye drops
- antimicrobial prophylaxis in surgery